Will Osimertinib emerge as the standard of care
By Park, sang-jun | translator Kang, Shin-Kook
24.06.10 05:21:00
°¡³ª´Ù¶ó
0
LAURA study results presented at ASCO 2024
Osimertinib reduces the risk of disease progression and death by 84%
The LAURA trial, which evaluated osimertinib¡¯s effect in patients with unresectable Stage III EGFR-mutant non-small cell lung cancer who received chemoradiotherapy (CRT), was presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The results were also concurrently published in NEJM.
The LAURA trial evaluated progression-free survival (PFS) in 216 patients with unresectable stage III EGFR-mutant NSCLC who received chemoradiotherapy (CRT). The patients were randomized to receive osimertinib or placebo.
The results showed a median PFS of 39.1 months and 5.6 months in the osimertinib and placebo arms, respectively, with an 84% reduction in the risk of dis
Park, sang-jun(lib6983@dailypharm.com)
If you want to see the full article, please JOIN US (click)